Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on October 1, 2025 at 4:30 PM EST to discuss its Regulation D 506(c) offering aiming to raise up to $5 million.
The webinar will feature presentations from key executives including CEO John Duffy, discussing Unbuzzd's clinically proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. The company plans to use the funds for direct-to-consumer expansion, distributor and retail growth, and to establish a path toward a potential IPO. Importantly, Quantum BioPharma shareholders will not face dilution from this offering.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato che il suo licenziatario, Unbuzzd Wellness, organizzerà un webinar per investitori il 1 ottobre 2025 alle 16:30 EST per discutere la sua offerta Regulation D 506(c) mirata a raccogliere fino a 5 milioni di dollari.
Il webinar presenterà interventi di dirigenti chiave, tra cui il CEO John Duffy, che parlerà della bevanda clinicamente provata di Unbuzzd che accelera il metabolismo dell’alcool e riduce i sintomi della borraccia. L’azienda intende utilizzare i fondi per l’espansione diretta al consumatore, la crescita di distributori e al dettaglio, e per definire un percorso verso una potenziale IPO. È importante che gli azionisti di Quantum BioPharma non subiranno diluizioni da questa offerta.
Quantum BioPharma (NASDAQ: QNTM) anunció que su licenciatario, Unbuzzd Wellness, organizará un seminario web para inversores el 1 de octubre de 2025 a las 4:30 PM EST para analizar su oferta Regulación D 506(c) con el objetivo de recaudar hasta $5 millones.
El seminario contará con presentaciones de ejecutivos clave, incluido el CEO John Duffy, quien discutirá la bebida clínicamente probada de Unbuzzd que acelera el metabolismo del alcohol y reduce los síntomas de la resaca. La compañía planea usar los fondos para la expansión directa al consumidor, el crecimiento de distribuidores y ventas minoristas, y para establecer un camino hacia una posible IPO. Es importante que los accionistas de Quantum BioPharma no enfrentarán dilución por esta oferta.
Quantum BioPharma (NASDAQ: QNTM)은 라이선스 보유자인 Unbuzzd Wellness가 2025년 10월 1일 오후 4:30(동부 표준시) 투자자 웨비나를 주최하여 Regulation D 506(c) 제안을 논의하고 최대 $5백만를 모으는 것을 발표했습니다.
웨비나에는 CEO John Duffy를 비롯한 주요 경영진의 발표가 포함되며, Unbuzzd의 임상적으로 검증된 음료가 알코올 대사를 가속화하고 숙취 증상을 감소시킨다고 논의합니다. 회사는 자금을 직접 소비자 확장, 유통업체 및 소매 성장, 그리고 잠재적 IPO를 위한 경로 설정에 사용할 계획입니다. 이 제안으로 Quantum BioPharma 주주들이 희석되지 않는 것이 중요합니다.
Quantum BioPharma (NASDAQ: QNTM) a annoncé que son licencié, Unbuzzd Wellness, organisera un webinaire investisseurs le 1 octobre 2025 à 16h30 EST pour discuter de son offre Regulation D 506(c) visant à lever jusqu’à 5 millions de dollars.
Le webinaire comprendra des présentations de cadres clés, dont le PDG John Duffy, qui discuteront de la boisson cliniquement prouvée d’Unbuzzd qui accélère le métabolisme de l’alcool et réduit les symptômes de la gueule de bois. L’entreprise prévoit d’utiliser les fonds pour l’expansion directe aux consommateurs, la croissance des distributeurs et du détail, et pour tracer une voie vers une éventuelle IPO. Il est important que les actionnaires de Quantum BioPharma ne subissent pas de dilution liée à cette offre.
Quantum BioPharma (NASDAQ: QNTM) kündigte an, dass sein Lizenznehmer Unbuzzd Wellness am 1. Oktober 2025 um 16:30 Uhr EST ein Investoren-Webinar ausrichten wird, um sein Regulation D 506(c)-Angebot zu besprechen, das darauf abzielt, bis zu $5 Millionen zu sammeln.
Das Webinar wird Präsentationen führender Geschäftsführer beinhalten, darunter CEO John Duffy, der Unbuzzds klinisch getestetes Getränk vorstellt, das den Alkoholstoffwechsel beschleunigt und Hangover-Symptome reduziert. Das Unternehmen plant, die Mittel für Direct-to-Consumer-Ausbau, Vertrieb und Einzelhandel zu verwenden und einen Weg zu einem potenziellen IPO zu ebnen. Wichtig ist, dass Quantum BioPharma-Aktionäre durch dieses Angebot nicht verwässert werden.
Quantum BioPharma (NASDAQ: QNTM) أعلنت أن مرخّصها الحصري، Unbuzzd Wellness، سيستضيف وبينار للمستثمرين في 1 أكتوبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة لمناقشة عرض Regulation D 506(c) الذي يهدف إلى جمع ما يصل إلى 5 ملايين دولار.
سيشمل الويبينار عروض من كبار التنفيذيين بما في ذلك الرئيس التنفيذي جون دافي، الذي سيتحدث عن مشروب Unbuzzd المؤكد سريريًا الذي يسرّع أيض الكحول ويقلل من أعراض hangover. تخطط الشركة لاستخدام الأموال في التوسع المباشر للمستهلك، ونمو الموزعين وتجزئة البيع بالتجزئة، وتحديد مسار نحو إدراج محتمل في البورصة. من المهم أن لا يتعثر مساهمو Quantum BioPharma بتخفيف من هذا العرض.
Quantum BioPharma（纳斯达克：QNTM）宣布，其许可方Unbuzzd Wellness将于2025年10月1日美国东部时间下午4:30举行投资者网络研讨会，讨论其Regulation D 506(c)发行，旨在募集最高$500万美元。
研讨会将由包括首席执行官John Duffy在内的关键高管发言，讨论Unbuzzd经临床验证的饮品如何加速酒精代谢、降低宿醉症状。公司计划使用资金用于直销扩张、经销商及零售渠道增长，并为潜在IPO铺路。重要的是，Quantum BioPharma的股东不会因此发行而被稀释。
- None.
- Licensee still requires significant capital for growth
- Early stage company dependent on successful fundraising
TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced its licensee – Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™ — the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, as part of its Reg D 506 (c) offering and up to
During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David will discuss the current investment opportunity for its scientifically backed beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms. Investors will also learn about Company leadership, and their path to scale distribution and retail sales. A question-and-answer session will follow the presentation. To register, please click here link.
CEO John Duffy commented, “We look forward to hosting potential investors for a discussion about how Unbuzzd is changing the way the world recovers from alcohol with our clinically proven wellness and recovery consumer product. We’ll also discuss the compelling opportunity for investors to be part of our success through our Regulation D 506(c) offering to raise up to US
A replay of the webinar will be available upon request by contacting investor@unbuzzd.com or 518-862-5993. To learn more about the Reg D 506(c) offering or begin your investment, please visit us at invest.unbuzzd.com
Quantum BioPharma shareholders will not be diluted by this offering.
About Unbuzzd Wellness Inc.
Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.
Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration ("BAC"), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include:
- Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects.
- Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.
- Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
- Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
- Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.
- No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.
The full press release of the clinical trial can be found here.
unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at https://unbuzzd.com.
Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.
8-pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks
To view an enhanced version of this graphic, please visit: link
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Unbuzzd Wellness, Inc.
John Duffy, Chief Executive Officer
Email: johnduffy@unbuzzd.com
Telephone: (508) 479-4923
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c9e3cc61-e716-405c-9534-5874a43a3915
FAQ
When is Unbuzzd Wellness hosting its investor webinar for QNTM shareholders?
How much is Unbuzzd Wellness looking to raise in their Reg D offering?
Will Quantum BioPharma (QNTM) shareholders be diluted by Unbuzzd's offering?
What will Unbuzzd use the $5 million funding for?
Who will be presenting at the Unbuzzd Wellness investor webinar?
